Dr. Naomi Walsh completed her PhD in Cancer Research from Dublin City University in 2008, and was awarded outstanding graduate researcher award from DCU’s Faculty of Science & Health. She also holds a Masters of Public Health (MPH) from University College Dublin. She conducted her post-doctoral research as a Cancer Prevention Fellow at the National Cancer Institute, USA. Upon her return to Ireland in 2015, Dr. Walsh held the HRB/Irish Cancer Society Cancer Prevention Fellow in the National Institute for Cellular Biotechnology, DCU. Subsequently, she received a Science Foundation Ireland Starter Investigator Research Grant (2016-2020) and established her research group. In 2017, she was awarded the Irish Cancer Society researcher of the year.

Dr. Walsh’s current research is focused on developing organotypic 3D cancer models to define and validate the biological consequences of genomic variants of pancreatic cancer. Her research aims to understand the development of pancreatic cancer, to uncover markers for early detection and to identify those at high risk of pancreatic cancer.
Other interests include understanding the tumour diversity caused by genomic alterations which contributes to cancer resistance to chemotherapy and molecular targeted therapies in breast and melanoma. Her lab uses genomic and functional NGS approaches to identify the mechanisms of genomic and immunological diversity to develop prognostic/predictive signatures and therapeutic strategies to overcome treatment resistance.